Faculty profile
Shirin Bonni
Back to facultyThis profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Calgary directory, so their courses may be missing. Find their university profile.
Research
Latest papers
PIAS1 Shapes a Tumor-Suppressive Microenvironment by Suppressing Immune Evasion in Oral Squamous Cell Carcinoma.
Cancers · 2025
Breast Tumor Metastasis and Its Microenvironment: It Takes Both Seed and Soil to Grow a Tumor and Target It for Treatment.
Cancers · 2024 · first author
ING1 inhibits Twist1 expression to block EMT and is antagonized by the HDAC inhibitor vorinostat.
European journal of cell biology · 2023
Latest funding
- $192,000
Regulation of Cellular Plasticity
NSERC · 2020 · Principal investigator
- $852,300
MGMT promoter methylated breast cancer: An opportunity for a targeted treatment with alkylating agent temozolomide in combination with existing breast cancer therapeutics.
CIHR · 2018 · Co-investigator
- $150,000
Epigenetic Regulation of Muscle Differentiation by the Chromatin Remodeling Protein ING2
NSERC · 2015 · Principal investigator
26 publications.
PIAS1 Shapes a Tumor-Suppressive Microenvironment by Suppressing Immune Evasion in Oral Squamous Cell Carcinoma.
Ghahremanifard P, An J, Chanda A, Chan AMY, Nakoneshny SC, Matthews TW, Chandarana SP, Hart RD, Hyrcza MD, Dort JC, Bonni S, Bose P
Breast Tumor Metastasis and Its Microenvironment: It Takes Both Seed and Soil to Grow a Tumor and Target It for Treatment.
Bonni S, Brindley DN, Chamberlain MD, Daneshvar-Baghbadorani N, Freywald A, Hemmings DG, Hombach-Klonisch S, Klonisch T, Raouf A, Shemanko CS, Topolnitska D, Visser K, Vizeacoumar FJ, Wang E, Gibson SB
ING1 inhibits Twist1 expression to block EMT and is antagonized by the HDAC inhibitor vorinostat.
Yang Y, Ma B, Djamshidi M, Zhang Q, Sarkar A, Chanda A, Tran U, Soh J, Sandall C, Chen HM, MacDonald JA, Bonni S, Sensen CW, Zheng J, Riabowol K
Sumoylated SnoN interacts with HDAC1 and p300/CBP to regulate EMT-associated phenotypes in mammary organoids.
Chanda A, Sarkar A, Deng L, Bonni A, Bonni S
Correction: PIAS1 and TIF1γ collaborate to promote SnoN SUMOylation and suppression of epithelial-mesenchymal transition.
Chanda A, Ikeuchi Y, Karve K, Sarkar A, Chandhoke AS, Deng L, Bonni A, Bonni S
PIAS1 and TIF1γ collaborate to promote SnoN SUMOylation and suppression of epithelial-mesenchymal transition.
Chanda A, Ikeuchi Y, Karve K, Sarkar A, Chandhoke AS, Deng L, Bonni A, Bonni S
TGF-β Mediated Immune Evasion in Cancer-Spotlight on Cancer-Associated Fibroblasts.
Ghahremanifard P, Chanda A, Bonni S, Bose P
Regulation of epithelial-mesenchymal transition and organoid morphogenesis by a novel TGFβ-TCF7L2 isoform-specific signaling pathway.
Karve K, Netherton S, Deng L, Bonni A, Bonni S
Recombinant human PRG4 (rhPRG4) suppresses breast cancer cell invasion by inhibiting TGFβ-Hyaluronan-CD44 signalling pathway.
Sarkar A, Chanda A, Regmi SC, Karve K, Deng L, Jay GD, Jirik FR, Schmidt TA, Bonni S
The Transcriptional Regulator SnoN Promotes the Proliferation of Cerebellar Granule Neuron Precursors in the Postnatal Mouse Brain.
Chen X, Chanda A, Ikeuchi Y, Zhang X, Goodman JV, Reddy NC, Majidi SP, Wu DY, Smith SE, Godec A, Oldenborg A, Gabel HW, Zhao G, Bonni S, Bonni A
Regulation of Cellular Plasticity
Principal investigators: Bonni, Shirin
Keywords: cell plasticity; morphology; transcriptional regulators; chromatin remodelers; cell polarity; cell differentiation; cell signaling
MGMT promoter methylated breast cancer: An opportunity for a targeted treatment with alkylating agent temozolomide in combination with existing breast cancer therapeutics.
Principal investigators: Morris, Donald G; Verma, Sunil
Keywords: Epigenetics; Mgmt; Olaparib; Parp Inhibition; Targeted Treatment; Temozolomide; Triple Negative Breast Cancer
Epigenetic Regulation of Muscle Differentiation by the Chromatin Remodeling Protein ING2
Principal investigators: Bonni, Shirin
Regulation of Transforming Growth Factor-ß Signaling and Responses
Principal investigators: Bonni, Shirin
Keywords: Cancer; Cell Cycle Progression; Cell Proliferation; Chromatin Immunoprecipitation Assays; Chromatin Remodeling; Epithelial-To-Mesenchymal Transition
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
Frequent collaborators
- Thomas Klonisch and Sabine Hombach-Klonisch: 50 shared papers
- Karl Riabowol and Shirin Bonni: 4 shared papers
- Andrew Freywald and Thomas Klonisch: 1 shared paper
- Andrew Freywald and Sabine Hombach-Klonisch: 1 shared paper
- Andrew Freywald and Edwin Wang: 1 shared paper
- Andrew Freywald and Shirin Bonni: 1 shared paper
- Karl Riabowol and Qingrun Zhang: 1 shared paper
- Thomas Klonisch and Edwin Wang: 1 shared paper
- Thomas Klonisch and Shirin Bonni: 1 shared paper
- Sabine Hombach-Klonisch and Edwin Wang: 1 shared paper
- Sabine Hombach-Klonisch and Shirin Bonni: 1 shared paper
- Edwin Wang and Shirin Bonni: 1 shared paper
- Justin Chun and Shirin Bonni: 1 shared paper
- Qingrun Zhang and Shirin Bonni: 1 shared paper
- Department of Biochemistry and Molecular Biology
- Department of Human Anatomy and Cell Science
- Biochemistry and Molecular Biology
- Oncology
- Medicine
- Department of Mathematics and Statistics
Co-authors at University of Calgary, colored by department. Thicker lines mean more shared papers; select anyone to open their profile and their own map.
Karl Riabowol
Department of Biochemistry and Molecular Biology
4 shared papers, latest 2023
Thomas Klonisch
Department of Human Anatomy and Cell Science
1 shared papers, latest 2024
Andrew Freywald
Oncology
1 shared papers, latest 2024
Edwin Wang
Department of Biochemistry and Molecular Biology
1 shared papers, latest 2024
Justin Chun
Medicine
1 shared papers, latest 2013
Qingrun Zhang
Department of Mathematics and Statistics
1 shared papers, latest 2023
Sabine Hombach-Klonisch
Department of Human Anatomy and Cell Science
1 shared papers, latest 2024
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.